Lorcaserin
Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It was approved by the Food and Drug Administration (FDA) in the United States in 2012. Lorcaserin is used in conjunction with diet and exercise to treat obesity. It works by controlling appetite — specifically by activating brain receptors for serotonin, a neurotransmitter that triggers feelings of satiety and satisfaction.
History[edit]
Lorcaserin was developed by Arena Pharmaceuticals, a biopharmaceutical company based in San Diego, California. The drug was approved by the FDA in June 2012 for adults with a Body Mass Index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Mechanism of Action[edit]
Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro, it is shown to act on these 5-HT2C receptors in the brain. The exact mechanism of action is not known, but it is believed to involve activation of these receptors in the pro-opiomelanocortin (POMC) system. Activation of these receptors in the POMC system is associated with satiety and decreased food consumption.
Side Effects[edit]
Common side effects of lorcaserin include headache, dizziness, fatigue, nausea, dry mouth, and constipation. In some cases, lorcaserin can cause serious side effects, such as serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors.
Withdrawal from Market[edit]
In February 2020, the FDA requested the withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. The FDA advised patients to stop taking lorcaserin and talk to their health care professionals about alternative weight-loss medicines and weight management programs.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
